Spelling suggestions: "subject:"warfare""
121 |
Estudo de utilização da varfarina em pacientes hospitalizados: análise do risco de interações medicamentosas e reações adversas / Study of warfarin utilization in hospitalized patients: analysis of risk of drug interactions and adverse reactionsCamilo Molino Guidoni 20 December 2012 (has links)
Introdução. A varfarina tem sido considerada a principal terapêutica anticoagulante oral há aproximadamente 50 anos, estando entre os dez medicamentos mais envolvidos com reações adversas a medicamentos (RAM), apresenta estreita janela terapêutica e complexo regime posológico, exibe enorme variabilidade doseresposta e elevado risco de interações medicamentosas (IM). Objetivo. Identificar e avaliar as IM e RAM relacionadas com a administração da varfarina. Casuística e Métodos. Trata-se de um estudo transversal. Os dados foram coletados retrospectivamente através do banco de dados informatizado do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo pertencente ao Sistema Único de Saúde. As prescrições de janeiro/2004 a dezembro/2010 dos pacientes que utilizaram varfarina foram analisadas, sendo os pacientes divididos em dois grupos: estudo (uso de vitamina K até 168 horas após prescrição de varfarina) e controle. Posteriormente, as prescrições medicamentosas que não continham varfarina foram excluídas da análise. As informações coletadas incluíram idade, gênero, raça, unidade de atendimento, diagnóstico clínico, doses e medicamentos, e exames laboratoriais. As IM com varfarina foram classificadas em risco A, B, C, D e X de acordo a base de dados da Lexi-Interact(TM) Online. Foi realizada análise descritiva e analítica (p<0,05). Resultados e Discussão. Foram identificados 3048 pacientes, os quais receberam 154161 prescrições medicamentosas (42120 continham varfarina). A idade média foi de 55,8 (±19,3) anos, 53,2% do gênero feminino, prevalência de idosos (48,1%) e do diagnóstico outras doenças cerebrovasculares específicas (4,3%). Os valores médios da international normalized ratio (INR) (2,4±1,7) e dose de varfarina (5,1±1,8mg) encontraram-se dentro dos preconizados pelos protocolos terapêuticos. Foi observado que 66,4% dos pacientes realizaram uso de polifarmácia, o que pode elevar o risco de IM. Além disso, 63,2% dos pacientes apresentaram prescrição(ões) de medicamentos classificados como risco D e/ou X, com média de 1,4 (±0,4) medicamento/prescrição, destacando-se o ácido acetilsalicílico e amiodarona. Quando comparado grupo de estudo (n=429) versus controle (n=2619), houve diferença estatisticamente significativa na idade média (anos) (59,0±18,8 vs. 55,5±19,3; p<0,000), número médio de medicamentos/prescrição (7,1±2,8 vs. 6,2±2,8; p<0,000), número médio de medicamentos de Risco D e X de IM por prescrição (1,4±1,3 vs. 1,0±1,0; p<0,000), albumina sérica (g/dL) (3,4±0,6 vs. 3,7±0,6; p<0,000), aspartato aminotransferase (U/L) (60,7± 200,6 vs. 41,5±84,5; p<0,005) e INR (4,9±3,4 vs. 2,1±0,7; p<0,000), fatores estes que podem ter contribuído para ocorrência de RAM no grupo de estudo. Conclusão. Observou-se elevada ocorrência de possíveis IM e RAM nos usuários de varfarina, as quais podem comprometer a efetividade e segurança do tratamento farmacológico. Como possíveis fatores de risco para ocorrência de RAM, destacam-se elevados valores de idade, número de medicamentos/prescrição, prescrição de medicamentos classificados como risco D e/ou X, de INR e de aspartato aminotransferase, e valores diminuídos de albumina sérica. / Introduction. Warfarin has been considered the main oral anticoagulant therapy about 50 years ago and is among the ten drugs most commonly involved in adverse drug reactions (ADR), has a narrow therapeutic index and complex dosage regimen, exhibits enormous variability dose-response and high risk drug-drug interactions (DDI). Objective. To Identify and evaluate DDI and ADR related to the administration of warfarin. Casuistry and Methods. This was a cross sectional study. Data were collected retrospectively through the computerized database of the Faculty of Medicine of Ribeirao Preto Hospital, University of Sao Paulo linked to the Unified Health System. The prescriptions of the January/2004 to December/2010 of patients using warfarin were analyzed, and the patients were divided into two groups: study (utilization of vitamin K until 168 hours after prescribing warfarin) and control. Thereafter, the drug prescriptions that did not contain warfarin were excluded from analysis. Information collected included age, gender, race, patient service center, clinical diagnosis, dosages and drugs, and laboratory exams. The warfarin DDI were classified at risk A, B, C, D and X according to the database Lexi-Interact (TM) Online. Descriptive and analytical analysis were performed (p<0.05). Results and Discussion. We identified 3048 patients who received 154,161 drug prescriptions (42,120 contained warfarin). The mean age was 55.8 (±19.3) years, 53.2% female, prevalence of elderly (48.1%) and other cerebrovascular diseases specific diagnosis (4.3%). The average values of international normalized ratio (INR) (2.4±1.7) and warfarin dose (5.1±1.8mg) were within those recommended by therapeutic protocols. It was observed that 66.4% of patients received polypharmacy, which can raise the risk of DDI. In addition, 63.2% of patients had prescription(s) of drugs classified as D or X risk, with an average of 1.4 (±0.4) drugs per prescription, especially aspirin and amiodarone. Compared study group (n=429) versus control (n =2619), there was a statistically significant difference in mean age (years) (59.0±18.8 vs. 55.5±19.3; p<0.000), average number of medications/prescriptions (7.1±2.8 vs. 6.2±2.8; p<0.000), mean number of drugs with risk D and X DDI/prescription (1.4±1.3 vs. 1.0±1.0, p<0.000), serum albumin (g/dL) (3.4±0.6 vs. 3.7±0.6; p<0.000), aspartate aminotransferases (U/L) (60.7±200.6 vs. 41.5±84.5; p<0.005) and INR (4.9±3.4 vs. 2.1±0.7; p<0.000), factors that may have contributed to the occurrence of ADR in the study group. Conclusion. There was a high occurrence of possible DDI and ADR in patients treated with warfarin, which may compromise the effectiveness and safety of pharmacological treatment. Noteworthy is the high values of age, number of medications/prescriptions, prescription drugs classified as risk D or X, INR and aspartate aminotransferases, and lower values of serum albumin as potential risk factors for the occurrence of ADR.
|
122 |
The influence of medication on the incidence, outcome, and recurrence of primary intracerebral hemorrhageHuhtakangas, J. (Juha) 13 November 2012 (has links)
Abstract
Intracerebral hemorrhage (ICH) is the most pernicious form of stroke, with high mortality. Warfarin-associated ICH (WA-ICH) carries an even higher mortality rate. The major reason for the high mortality is explained by early hematoma growth. Warfarin use has rapidly increased with the aging of the population.
We investigated temporal trends in the incidence and outcome of WA-ICHs. We found that although the proportion of warfarin users almost quadrupled in our population, the annual incidence and case fatality of WA-ICHs decreased.
Management of ICH is mostly supportive. Prevention of associated complications is the issue in improving outcome. Hypertension is the most important modifiable risk factor for primary ICH, but little is known of the effect of preceding hypertension on outcome. Aggressive lowering of blood pressure is suggested to be a feasible treatment option. Reversal of warfarin anticoagulation with prothrombin complex concentrate (PCC) has been implemented as an acute treatment option for patients with WA-ICH.
We found that the survival of WA-ICH subjects among our population improved after implementation of reversal of warfarin anticoagulation with PCC, likely because of the introduction of PCC.
Because high mean arterial blood pressure (BP) at admission is an independent predictor of early death in patients with ICH, we explored its role in survival and poor outcome separately in normotensive subjects and subjects with treated and untreated hypertension. We found that despite their higher BP values at admission, subjects with untreated hypertension showed better survival and more often a favorable outcome after BP-lowering therapy than other patients.
Studies on recurrent ICH are scarce. Underlying comorbidities, prior strokes, and drug-induced impaired platelet function may increase the risk for primary ICH (PICH). A lobar location of primary ICH may predict recurrent ICH. We investigated whether these factors predicted recurrence of PICH. In our study the annual incidence of recurrent ICH was 1.67%. Cumulative 5- and 10-year incidences were 9.6% and 14.2%. In multivariable analyses, prior ischemic stroke and diabetes proved to be independent predictors for recurrence. Moreover, diabetes was an independent risk factor for fatal recurrent PICH. Use of aspirin and serotonergic drugs did not significantly contribute to the risk. / Tiivistelmä
Aivoverenvuoto (ICH) on aivoverenkiertohäiriöistä vakavin. Sille on tyypillistä korkea kuolleisuus erityisesti varfariinihoitoon liittyen, ja eloonjääneetkin vammautuvat usein vakavasti. Verenvuodon koon kasvu alkuvaiheessa selittänee korkean kuolleisuuden. Väestön ikääntymisen myötä varfariinin käyttö on lisääntynyt nopeasti.
Aivoverenvuodon hoito perustuu pitkälti ennusteen parantamiseen komplikaatioita estämällä. Verenpaine on tärkein hoidettavissa oleva riskitekijä, mutta tutkimustieto akuutin vaiheen verenpainetason merkityksestä ennusteeseen on vähäistä. Tehokasta verenpaineen alentamista alkuvaiheessa pidetään lupaavana hoitomenetelmänä. Vuodon koon kasvua pyritään rajoittamaan kumoamalla varfariinin antikoaguloiva vaikutus protrombiinikompleksi-konsentraatilla (PCC).
Väitöstyössäni selvitän varfariinin käyttöön liittyvien aivoverenvuotojen (WA-ICH) esiintymistiheyttä ja ennustetta ajan myötä. Tutkin myös vuodon koon kasvun rajoittamista ja alkuvaiheen korkean verenpaineen alentamista hoitomenetelminä sekä selvitän, mitkä tekijät johtavat ICH:n uusiutumiseen.
Totesimme WA-ICH:n ilmaantuvuuden ja tapauskuolleisuuden pienentyneen, vaikka varfariinin käyttö miltei nelinkertaistui väestössämme. Toisaalta WA-ICH -potilaiden kuolleisuus pieneni PCC-hoidon aloittamisen jälkeen, mahdollisesti sen ansiosta.
Tutkiessamme riippumattomasti varhaista kuolemaa ennustavan korkean tulovaiheen verenpaineen roolia normaaliverenpaineisilla, hoidettua ja hoitamatonta verenpainetautia sairastavilla totesimme hoitamattomien hypertonia-potilaiden selvinneen akuutin vaiheen lääkehoidon myötä muita useammin hengissä ja hyväkuntoisina korkeista tulovaiheen verenpainearvoista huolimatta.
Aivoverenvuodon uusiutumiseen vaikuttavista tekijöistä on vähän tutkimustietoa. Muu sairastavuus, aiemmat aivoverenkiertohäiriöt ja trombosyyttien toimintaan vaikuttavat lääkkeet saattavat lisätä ICH:n uusiutumisriskiä. Totesimme vuosittaisen uuden ICH:n esiintymistiheyden olevan 1,67 %. Aikaisempi aivoinfarkti ja diabetes osoittautuivat riippumattomiksi uusiutumista ennustaviksi riskitekijöiksi, minkä lisäksi diabetes ennusti kuolemaan johtavaa uutta ICH:a. Asetyylisalisyylihapon ja selektiivisten serotoniinin takaisinoton estäjien käyttäminen ei vaikuttanut merkittävästi uusiutumisriskiin.
|
123 |
Oral anticoagulation and stroke riskSjögren, Vilhelm January 2017 (has links)
Background: The risk of ischaemic stroke in patients with atrial fibrillation (AF) and mechanical heart valve (MHV) prostheses can be reduced by oral anticoagulation (OAC), which increases the risk of serious bleeding. The aims of this thesis were [1] to find out how effective and safe warfarin is where treatment quality is high, i.e. Sweden, with proportion of time that patients spend within the therapeutic range (TTR) >70%, [2] whether there is evidence for administering low-molecular-weight heparin (LMWH) during temporary interruptions of OAC (bridging therapy), and whether non-vitamin K-dependent oral anticoagulants (NOACs) as a group, [3] or individually, [4] are more effective and safer than warfarin when used for stroke prevention in patients with AF. Materials and methods: All four studies were retrospective, based on the Swedish anticoagulation register Auricula, and done with merging of data from some or all of the National Patient Register, the Prescribed Drug Register, the Swedish Stroke Register (Riksstroke), and the Cause of Death Register. In studies 2–4, propensity score matching was performed to obtain treatment groups with similar risk profiles. Outcomes were defined as haemorrhages or thromboses requiring specialist care, or death. Haemorrhages were intracranial, gastrointestinal, or other. Thromboses were ischaemic stroke, systemic embolism, myocardial infarction, or venous thromboembolism (VTE). Study 1 described all patients on warfarin during 2006–2011, which was before the introduction of NOACs. Study 2 was a cohort study of all patients who had a planned interruption of warfarin during the same period. Study 3 included all 49,011 patients starting OAC for stroke prevention due to AF between 1 July 2011 and 31 December 2014, and study 4 all 64,382 patients with the same indication between 1 January 2013 and 31 December 2015. Results: Study 1 showed that for the 77,423 patients on warfarin with 217,804 treatment years, TTR was 77.4% for patients with AF, 74.5% with MHV, and 75.9% with VTE. Annual rates of intracranial bleeding were 0.38%, 0.51%, and 0.30%. In study 2, with 14,556 warfarin interruptions, the 30-day risk of a bleeding requiring specialist care was 0.64% for LMWH treated and 0.46% for controls. For patients with VTE as indication for OAC, bleeding rate with LMWH was significantly higher at 0.85% vs. 0.16% (hazard ratio 5.24, 95% confidence interval 1.39–19.77), but with no difference for patients with MHV or AF. The incidence of ischaemic complications was higher in the LMWH bridging group overall and for patients with MHV and AF, but not for patients with VTE. In study 3, for the 12,694 patients starting NOAC (10,392 treatment years) or matched warfarin patients (9,835 treatment years, TTR 70%) due to AF, annual incidence of ischaemic stroke and systemic embolism did not differ between the groups (1.35% vs. 1.58%), but risks of major bleedings and intracranial bleedings were significantly lower: 2.76% vs. 3.61% and 0.40% vs. 0.69%. In study 4, patients on individual NOACs (6,574 dabigatran, 8,323 rivaroxaban, 12,311 apixaban) were compared to 37,174 patients starting warfarin (in total 81,176 treatment years). No NOAC showed any difference in risk of ischaemic stroke or systemic embolism, but there were fewer intracranial bleedings, serious bleedings overall, and deaths for dabigatran and apixaban compared to warfarin. For patients starting rivaroxaban the risk of gastrointestinal bleeding was higher than for matched warfarin counterparts, with no significant differences in other bleeding risks, or mortality. Conclusions: Swedish warfarin treatment shows TTR levels that are high by international standards, correlating to low incidences of ischaemic and haemorrhagic events. LMWH bridging has not been proven beneficial, even for patients with MHV, meaning that bridging in general cannot be recommended. NOACs as a group were safer than high-quality warfarin treatment. Efficacy did not differ, even when comparing individual NOACs to warfarin, but there were fewer bleedings on dabigatran and apixaban. Although not more efficient than warfarin with a high TTR, NOACs should be the recommended first choice for OAC in AF, on the merit of lower bleeding risks. / <p>Finansiär: Forskning och Utveckling, Region Västernorrland</p>
|
124 |
Referensintervall för protein C och fritt protein S vid warfarinbehandling / Reference Intervals for Protein C and Free Protein S During Warfarin TreatmentEriksson, Wilma January 2022 (has links)
No description available.
|
125 |
Anticoagulation Review: A Primer for the Home Health Care ProviderStewart, David W., Gentry, Chad, Freshour, Jessica 01 April 2012 (has links)
Anticoagulants, also known as antithrombotics, are among the most commonly prescribed medications in the United States. Understanding how these medications work, the propensity for interactions with other drugs, dietary factors, and disease states is important for clinicians assessing and providing care to patients in all environments. In this review, we seek to provide essential information for the home health care provider for evaluating patients receiving anticoagulants commonly prescribed in the home health care setting. The low-molecular-weight heparins and vitamin K antagonists are the most commonly used agents for outpatient anticoagulation. New agents, such as the direct factor Xa inhibitors and direct thrombin inhibitors have recently been approved with additional new agents in the approval process and development pipeline. We seek to review the most pertinent information for each of these classes of medications providing information on pharmacology, interactions with other drugs, diet, and diseases and important clinical information.
|
126 |
Coumarin-based molecular probes : exploring the spectroscopic properties of complex mixtures and applications in colloid chemistryZhao, Shangqing January 2018 (has links)
Warfarin is a well-known anticoagulant drug that is used to prevent cardiovascular disease and blood coagulation such as thrombosis. In this study, the main aim was to investigate the photo physical characteristics of warfarin in the different molecular environments provided by sodium dodecyl sulfate (SDS) micelles by using ultraviolet absorption and fluorescence emission spectroscopic techniques. Warfarin and a structural analogue not existing in solution as a cyclic hemiketal, phenprocoumon, were mixed with different concentrations of SDS and spectral changes for these warfarin and phenprocoumon were recorded. Interestingly, results demonstrated, based on an evident increase in the absorption intensity at 273 nm and an evident blue shift in the fluorescence emission spectrum after the addition of an increasing concentration of SDS, that primarily the cyclic hemiketal isomer of warfarin was found to be solvated by SDS micelles at an apparent recorded critical micelle concentration of ~8mM. Altogether these observations suggest that warfarin may be used as a molecular probe to explore the polarities of complex colloidal mixtures. Moreover, the possibility of using micelles for controlling the isomeric state of warfarin is interesting and can potentially be used for better controlling dosage of warfarin thereby reducing side effects.
|
127 |
Warfarin-induced vitamin K deficiency is associated with cognitive and behavioral perturbations, and alterations in brain sphingolipids in ratsTamadon-Nejad, Sahar 05 1900 (has links)
La Vitamine K (VK) est largement reconnue pour son rôle dans la coagulation sanguine toutefois, de plus en plus de travaux indiquent son implication dans la fonction cérébrale. La VK est requise pour l'activation de différentes protéines, par exemple la protéine Gas6, et la ménaquinone-4 (MK-4), le principal vitamère K dans le cerveau, est impliquée dans le métabolisme des sphingolipides. Dans un rapport précédent, nous avons montré qu'un régime alimentaire faible en VK tout au long de la vie était associé à des déficits cognitifs chez des rats âgés. La warfarine sodique est un puissant antagoniste de la VK qui agit en bloquant le cycle de la VK, provoquant un «déficit relatif de VK » au niveau cellulaire. À la lumière du rôle
émergent de la VK dans le cerveau, la warfarine pourrait représenter un facteur de risque pour la fonction cérébrale. Ce travail est donc pertinente en raison de la forte proportion d'adultes traîtés à la warfarine sodique. Dans la présente étude, 14 rats mâles Wistar ont été traités avec 14 mg de warfarine/kg /jour (dans l'eau potable) et des injections sous-cutanées de VK (85 mg/kg), 3x/sem, pendant 10 semaines. Quatorze rats témoins ont été traités avec de l'eau normale et injectés avec une solution saline. Les rats ont été soumis à différents tests comportementaux après quoi les niveaux de phylloquinone, MK-4, sphingolipides (cérébroside, sulfatide, sphingomyéline, céramide et gangliosides), et les sous-types de gangliosides (GT1b, GD1a, GM1, GD1b), ont été évalués dans différentes régions du cerveau. Comparativement aux rats du groupe contrôle, les rats traités à la warfarine présentaient des latences plus longues au test de la piscine de Morris (p <0,05) ainsi qu'une hypoactivité et un comportement exploratoire plus faible au test de « l’open field » (p <0,05). Le traitement par warfarine a également entraîné une diminution spectaculaire du niveau de MK-4 dans toutes les régions du cerveau (p <0,001), une altération des concentrations de sphingolipidiques, en particulier dans le cortex frontal et le mésencéphale
(p <0,05), et une perte de différences régionales sphingolipidiques, notamment pour les
gangliosides. Le traitement par warfarine a été associé à un niveau inférieur de GD1a dans l'hippocampe et un niveau supérieur de GT1b dans le cortex préfrontal et le striatum. En
conclusion, la déficience en VK induite par warfarine altère les niveaux de VK et sphingolipides dans le cerveau, avec de potentiels effets néfastes sur les fonctions cérébrales. / Vitamin K (VK) is widely known for its role in blood coagulation, however many studies suggest its involvement in brain function. VK is required for the activation of various cerebral proteins (e.g., Gas6) and menaquinone-4 (MK-4), the main K vitamer in brain, is involved in sphingolipid metabolism. Furthermore, life-long intake of a low VK diet has been associated with cognitive deficits in old rats. Warfarin (W) is a potent VK antagonist that acts by blocking the VK cycle causing a “relative VK deficiency” at the cellular level. In light of this and the emerging role of VK in brain, W could represent a risk factor for cerebral function. The finding of this study is important according to the large proportion of adults with thromboembolic diseases being treated with warfarin drugs. This study was conducted in a rat model where the impact of W was investigated with respect to cognition, behavior, and brain menaquinone-4 (MK-4) and sphingolipid status. Fourteen Wistar male rats were treated with 15 mg W/kg/d (in drinking water) and subcutaneous VK (85 mg/kg), 3X/wk, for 10 wks; 14 control rats were treated with normal water and injected with saline. At the end of the treatment period, rats were subjected to different behavioral tests, afterwhich their brains assessed for VK (phylloquinone and MK-4) and sphingolipids (gangliosides, ceramides, cerebrosides, sphingomyelin and sulfatides) and gangliosides subtypes (GT1b, GD1a, GM1, GD1b). Mean latencies to find the hidden platform were higher in the W compared to the control group (p<0.05) suggesting cognitive deficits as well as hypoactivity and lower exploratory behaviour in the open field test (p<0.05). Warfarin treatment also resulted in a dramatic decrease in MK-4 concentration in all brain regions (p<0.001), altered sphingolipid level, especially in frontal cortex and midbrain (p<0.05), and in a loss of sphingolipid regional differences, notably for gangliosides. W treatment was associated with lower GD1a in the hippocampus and higher GT1b in the striatum and prefrontal cortex. In conclusion, warfarin-induced VK deficiency alters VK and sphingolipid status in brain with potential detrimental effects on brain functions.
|
128 |
Étude pharmacogénomique de la warfarine et de l'activité physiqueRouleau-Mailloux, Étienne 04 1900 (has links)
La warfarine est un médicament anticoagulant possédant un faible index thérapeutique et une grande variabilité intra et interindividuelle dans la réponse au traitement. Les facteurs déterminants de la réponse à la warfarine ne sont pas tous connus et la présente étude vise à tester l'hypothèse que la pratique régulière d’activité physique puisse y être associée. Nous avons évalué si l’activité physique, mesurée à l’aide de 2 questionnaires différents, était associée à la dose de warfarine et au pourcentage de temps passé à l'intérieur de l'intervalle thérapeutique ciblé (time in therapeutic range : TTR).
L’étude a été menée chez les 1064 participants de la Cohorte warfarine de l’Institut de Cardiologie de Montréal (ICM) et chez 618 utilisateurs de warfarine issus de la Biobanque de l’ICM.
Nous avons trouvé que, dans les deux cohortes, les patients actifs nécessitaient une dose hebdomadaire moyenne plus élevée que les patients inactifs. L’association perdurait lorsque le modèle statistique était ajusté pour différentes variables connues pour influencer la réponse à la warfarine, telles que le génotype aux gènes CYP2C9 et VKORC1, l’âge, la taille, le poids, et l’INR ciblé. L’INR ciblé est décidé par le médecin et il correspond généralement à 2,0 – 3,0 ou 2,5 – 3,5. Les patients de la Cohorte warfarine avaient aussi plus de chances d’avoir un TTR inférieur à 60%, donc d’être moins stables.
La pratique régulière d’activité physique est donc un facteur déterminant de la dose thérapeutique de warfarine et la pratique d'activité physique intensive est associée à un TTR plus faible. / Warfarin is an oral anticoagulant agent with a narrow therapeutic index. Dosing of warfarin is highly variable among patients and it may also vary in time for the same patient. All factors influencing warfarin response are not known and this study aims to elucidate if regular physical activity is one important factor. We evaluated whether warfarin dosage and the time in therapeutic range (TTR) were associated with RPA. RPA was measured via 2 different questionnaires.
The study was conducted by using 1,064 patients in the Quebec Warfarin Cohort (QWC) and 618 patients from the Genetic-Hospital Cohort. Both cohorts are hosted at the Montreal Heart Institute.
In both cohorts, we found that active patients required higher weekly doses of warfarin than inactive patients. The association was maintained when the model was adjusted for variables known to influence warfarin response, i.e. CYP2C9 and VKORC1 genotypes, age, height, weight and targeted INR. The targeted INR is fixed by the physicist and is usually between 2.0 and 3.0 or between 2.5 or 3.5. Active patients from the QWC were more susceptible to have a TTR inferior to 60%, i.e. to be unstable.
RPA influences warfarin response and intensive RPA is associated with a greater instability in treatment response.
|
129 |
Warfarin-induced vitamin K deficiency is associated with cognitive and behavioral perturbations, and alterations in brain sphingolipids in ratsTamadon-Nejad, Sahar 05 1900 (has links)
La Vitamine K (VK) est largement reconnue pour son rôle dans la coagulation sanguine toutefois, de plus en plus de travaux indiquent son implication dans la fonction cérébrale. La VK est requise pour l'activation de différentes protéines, par exemple la protéine Gas6, et la ménaquinone-4 (MK-4), le principal vitamère K dans le cerveau, est impliquée dans le métabolisme des sphingolipides. Dans un rapport précédent, nous avons montré qu'un régime alimentaire faible en VK tout au long de la vie était associé à des déficits cognitifs chez des rats âgés. La warfarine sodique est un puissant antagoniste de la VK qui agit en bloquant le cycle de la VK, provoquant un «déficit relatif de VK » au niveau cellulaire. À la lumière du rôle
émergent de la VK dans le cerveau, la warfarine pourrait représenter un facteur de risque pour la fonction cérébrale. Ce travail est donc pertinente en raison de la forte proportion d'adultes traîtés à la warfarine sodique. Dans la présente étude, 14 rats mâles Wistar ont été traités avec 14 mg de warfarine/kg /jour (dans l'eau potable) et des injections sous-cutanées de VK (85 mg/kg), 3x/sem, pendant 10 semaines. Quatorze rats témoins ont été traités avec de l'eau normale et injectés avec une solution saline. Les rats ont été soumis à différents tests comportementaux après quoi les niveaux de phylloquinone, MK-4, sphingolipides (cérébroside, sulfatide, sphingomyéline, céramide et gangliosides), et les sous-types de gangliosides (GT1b, GD1a, GM1, GD1b), ont été évalués dans différentes régions du cerveau. Comparativement aux rats du groupe contrôle, les rats traités à la warfarine présentaient des latences plus longues au test de la piscine de Morris (p <0,05) ainsi qu'une hypoactivité et un comportement exploratoire plus faible au test de « l’open field » (p <0,05). Le traitement par warfarine a également entraîné une diminution spectaculaire du niveau de MK-4 dans toutes les régions du cerveau (p <0,001), une altération des concentrations de sphingolipidiques, en particulier dans le cortex frontal et le mésencéphale
(p <0,05), et une perte de différences régionales sphingolipidiques, notamment pour les
gangliosides. Le traitement par warfarine a été associé à un niveau inférieur de GD1a dans l'hippocampe et un niveau supérieur de GT1b dans le cortex préfrontal et le striatum. En
conclusion, la déficience en VK induite par warfarine altère les niveaux de VK et sphingolipides dans le cerveau, avec de potentiels effets néfastes sur les fonctions cérébrales. / Vitamin K (VK) is widely known for its role in blood coagulation, however many studies suggest its involvement in brain function. VK is required for the activation of various cerebral proteins (e.g., Gas6) and menaquinone-4 (MK-4), the main K vitamer in brain, is involved in sphingolipid metabolism. Furthermore, life-long intake of a low VK diet has been associated with cognitive deficits in old rats. Warfarin (W) is a potent VK antagonist that acts by blocking the VK cycle causing a “relative VK deficiency” at the cellular level. In light of this and the emerging role of VK in brain, W could represent a risk factor for cerebral function. The finding of this study is important according to the large proportion of adults with thromboembolic diseases being treated with warfarin drugs. This study was conducted in a rat model where the impact of W was investigated with respect to cognition, behavior, and brain menaquinone-4 (MK-4) and sphingolipid status. Fourteen Wistar male rats were treated with 15 mg W/kg/d (in drinking water) and subcutaneous VK (85 mg/kg), 3X/wk, for 10 wks; 14 control rats were treated with normal water and injected with saline. At the end of the treatment period, rats were subjected to different behavioral tests, afterwhich their brains assessed for VK (phylloquinone and MK-4) and sphingolipids (gangliosides, ceramides, cerebrosides, sphingomyelin and sulfatides) and gangliosides subtypes (GT1b, GD1a, GM1, GD1b). Mean latencies to find the hidden platform were higher in the W compared to the control group (p<0.05) suggesting cognitive deficits as well as hypoactivity and lower exploratory behaviour in the open field test (p<0.05). Warfarin treatment also resulted in a dramatic decrease in MK-4 concentration in all brain regions (p<0.001), altered sphingolipid level, especially in frontal cortex and midbrain (p<0.05), and in a loss of sphingolipid regional differences, notably for gangliosides. W treatment was associated with lower GD1a in the hippocampus and higher GT1b in the striatum and prefrontal cortex. In conclusion, warfarin-induced VK deficiency alters VK and sphingolipid status in brain with potential detrimental effects on brain functions.
|
130 |
Rôles des polymorphismes génétiques dans la détermination de la dose individuelle de la warfarine chez les patients traités avec de l’amiodaroneBahroun, Imen 05 1900 (has links)
Introduction : Bien que la pratique de l’usage de la warfarine se soit améliorée au cours de la dernière décennie, aucune recommandation claire basée sur le dosage de l’amiodarone n’a été jusqu’à maintenant standardisée, ce qui représente un grand obstacle pour les cliniciens. La warfarine a un index thérapeutique étroit nécessitant un suivi régulier et un ajustement individuel de la posologie, ceci afin de déterminer la dose thérapeutique, tout en prévenant les effets secondaires qui pourraient être fatals dans certains cas. La variabilité interindividuelle de la réponse à la warfarine dépend de plusieurs facteurs, dont l’âge, le sexe, le poids, l’alimentation et l’interaction médicamenteuse, mais ceux-ci n’expliquent que partiellement les différences de sensibilité à la warfarine. Les polymorphismes des gènes CYP2C9 et VKORC1 jouent un rôle important dans la réponse à la warfarine et expliquent jusqu’à 50% de la variabilité des doses. L’utilisation d’antiarythmiques telle l’amiodarone peut accentuer considérablement l’effet de la warfarine et nécessite généralement une diminution de 30 à 50% de la dose de la warfarine. Aucune étude à ce jour n’a tenté de déterminer l’utilité du génotypage des polymorphismes des gènes CYP2C9 et VKORC1 chez les patients sous traitement combiné de warfarine et amiodarone.
Objectif : Notre étude a pour objectif tout d’abord de déterminer si des facteurs génétiques influencent la première dose de stabilisation de la warfarine chez les patients en FA après l’introduction de l’amiodarone. Nous allons également tenter de confirmer l’association préalablement rapportée entre les facteurs génétiques et la première dose de stabilisation de warfarine dans notre population à l’étude.
Méthodes : Un devis de cohorte rétrospective de patients qui fréquentaient la clinique d'anticoagulothérapie de l’Institut de cardiologie de Montréal entre le 1er janvier 2007 et le 29 février 2008 pour l’ajustement de leur dose selon les mesures d'INR. Au total, 1615 patients ont été recrutés pour participer à cette étude de recherche. Les critères de sélection des patients étaient les patients avec fibrillation auriculaire ou flutter, ayant un ECG documenté avec l'un de ces deux diagnostics et âgé de moins de 67 ans, en raison d’une moindre comorbidité. Les patients souffrant d’insuffisance hépatique chronique ont été écartés de l’étude. Tous les patients devaient signer un consentement éclairé pour leur participation au projet et échantillon de sang a été pri pour les tests génétiques. La collecte des données a été effectuée à partir du dossier médical du patient de l’Institut de cardiologie de Montréal. Un formulaire de collecte de données a été conçu à cet effet et les données ont ensuite été saisies dans une base de données SQL programmée par un informaticien expert dans ce domaine. La validation des données a été effectuée en plusieurs étapes pour minimiser les erreurs. Les analyses statistiques utilisant des tests de régression ont été effectuées pour déterminer l’association des variants génétiques avec la première dose de warfarine.
Résultats : Nous avons identifié une association entre les polymorphismes des gènes CYP2C9 et VKORC1 et la dose de la warfarine. Les polymorphismes génétiques expliquent jusqu’à 42% de la variabilité de dose de la warfarine. Nous avons également démontré que certains polymorphismes génétiques expliquent la réduction de la dose de warfarine lorsque l’amiodarone est ajoutée à la warfarine.
Conclusion : Les travaux effectués dans le cadre de ce mémoire ont permis de démontrer l’implication des gènes CYP2C9 et VKORC1 dans la réponse au traitement avec la warfarine et l’amiodarone. Les résultats obtenus permettent d’établir un profil personnalisé pour réduire les risques de toxicité, en permettant un dosage plus précis de la warfarine pour assurer un meilleur suivi des patients. Dans le futur, d’autres polymorphismes génétiques dans ces gènes pourraient être évalués pour optimiser davantage la personnalisation du traitement. / Background: Although the practice of the use of warfarin has improved during the last decade, no clear recommendation based on the determination of Amiodarone has been standardized until now, which is a major obstacle for clinicians. Warfarin has a narrow therapeutic index requiring regular monitoring and an individual dose ajustement, to this determines the therapeutic dose, while avoiding the side effects that could be fatal in some cases. The interindividual variability to the Warfarin depends on several factoring age, sex, weight, food and drug interactions but they only partially explain the differences in sensitivity to Warfarin. The polymorphisms of the genes CYP2C9 and VKORC1 play an important role in the response to the Warfarine and explain 50% of the variability of doses.The use of antiarrhythmic Amiodarone can greatly enhancethe effect of Warfain and generally requires a reduction of 30-50% of the dose of Warfarin. No study to date has attempted to determine the utility of genotyping polymorphisms of CYP2C9 and VKORC1 in patients on combination therapy of Warfarin and Amiodarone.
Objectives: Our study aims to first determine if genetic factors influence the first dose stabilization of Warfarin in patients with AF after the introduction of Amiodarone. We will also attempt to confirm the previously reported between genetic association and the first dose of Warfarin stabilization in our study population.
Methods: A retrospective cohort of all patients who frequent the clinic Warfarin of Montreal Heart Institute between 01/01/2007 and 02/30/2008 for the adjustment of their INR. The total of 1615 patients were recruited. The criteria for selection were patients with atrial fibrillation or flutter, with ECG documented with one of these tow diagnostic and younger than 67 years because of reduced morbidity. Patients with chronic liver disease were excluded from the study. All patients had to sign an informed consent for their participation in the project to which they contributed 15 ml of blood for genetic testing. Data collection was conducted from the patient's medical record of the Montreal Heart Institute. A data collection form was designed for this purpose and the data were then entered into a SQL database programmed by a computer expert in this field. Data validation was performed in several steps to minimize errors. Statistical analysis using regression tests were conducted to determine the association of genetic variants with the first dose of Warfarin.
Results: We identified an association between polymorphisms of the genes CYP2C9 and VKORC1 and warfarin dose. Genetic polymorphisms to explain 42% of the variability in dose of Warfarin. We also demonstrated that genetic polymorphisms explain the reduction in the dose of Warfarin when Amiodarone is added to Warfarin.
Conclusion: Our Work in the context of this thesis have shown the involvement of CYP2C9 and VKORC1 genes in response to treatment with Warfarin and Amiodarone. The results are used to create a personalized profile to reduce the risk of toxicity, enabling a more accurate dosing of warfarin for better monitoring of patients. In the future, other genetic polymorphisms in these genes could be evaluated to optimize the value of personalised therapy.
|
Page generated in 0.0556 seconds